Abstract: The invention relates to an improved composition of ferric maltol or ferric trimaltol for the treatment of iron deficiency, wherein the composition comprises the active ferric maltol or ferric trimaltol lower than 60% of the total composition weight. The compositions further can be a capsule or tablet or any other pharmaceutical solid dosage form, preferably a capsule in a hard gelatin in a size of 0 or 1, for oral administration.

Abstract: Described herein does a sterile protective cover comprise an intracameral therapeutic agent delivery device in the form of a pen-injector comprising a cartridge container for dispensing multiple doses of a medicament, coupled to an actuation assembly within a housing. A needle assembly is coupled to the distal end of the cartridge container, provided with a removable cap received within the housing will be in optional pre-sterile or no-sterile condition. Use of such device for the prevention or treatment of ocular conditions or diseases is also disclosed. A sterile protective cover comprising ophthalmic device, wherein the sterile protective cover is made of plastic, polythene, polyethylene, resin, rubber, polystyrene, polypropylene, polycarbonate, nylon, or combination thereof.

Abstract: The present invention relates to a rectal delivery device in the form of a syringe with improved locking mechanism for the delivery of an appropriate dosage of a medicament, thereby minimizing errors. More particularly, the present invention provides syringes with improved lock control units for delivering diazepam formulations for the treatment of patients experiencing epileptic seizures.

Abstract: The present invention relates to novel, improved processes for the preparation of sodium glucose co-transporter 2 (SGLT-2) inhibitors and novel intermediates thereof. More particularly, the present invention relates to a novel, improved process for the preparation of gliflozin compounds such as empagliflozin and dapagliflozin, intermediates thereof. The product obtained from the processes of present invention may be amorphous or crystalline, or in the form of amorphous/crystalline solid dispersions/solutions with pharmaceutically acceptable polymers and preparation process thereof. Also, the products obtained from the present invention may be used for the preparation of medicaments for the prevention and/or treatment of diseases and conditions associated with SGLT-2 inhibition.

Abstract: The present invention discloses novel devices, methods, and formulations for multiple dose delivery of an appropriate formulation of Heparin or low molecular weight heparin or a heparin-like compound. Multiple dose formulations of fondaparinux sodium, and preparation methods thereof, are also disclosed.

Abstract: The present invention relates to novel, improved processes for the preparation of sodium glucose co-transporter 2 (SGLT-2) inhibitors and novel intermediates thereof. More particularly, the present invention relates to a novel, improved process for the preparation of gliflozin compounds such as empagliflozin and dapagliflozin, intermediates thereof. The product obtained from the processes of present invention may be amorphous or crystalline, or in the form of amorphous/crystalline solid dispersions/solutions with pharmaceutically acceptable polymers and preparation process thereof. Also, the products obtained from the present invention may be used for the preparation of medicaments for the prevention and/or treatment of diseases and conditions associated with SGLT-2 inhibition.

Abstract: Described herein does a sterile protective cover comprise an intracameral therapeutic agent delivery device in the form of a pen-injector comprising a cartridge container for dispensing multiple doses of a medicament, coupled to an actuation assembly within a housing. A needle assembly is coupled to the distal end of the cartridge container, provided with a removable cap received within the housing will be in optional pre-sterile or no-sterile condition. Use of such device for the prevention or treatment of ocular conditions or diseases is also disclosed. A sterile protective cover comprising ophthalmic device, wherein the sterile protective cover is made of plastic, polythene, polyethylene, resin, rubber, polystyrene, polypropylene, polycarbonate, nylon, or combination thereof.

Abstract: Described herein is a sterile protective cover comprising an intracameral therapeutic agent delivery device in the form of a pen-injector comprising a cartridge container for dispensing multiple doses of a medicament, coupled to an actuation assembly within a housing. In some forms a needle assembly is coupled to the distal end of the cartridge container, provided with a removable cap received within the housing will be in optional pre-sterile or no-sterile condition. Use of such device for the prevention or treatment of ocular conditions or diseases is also disclosed. A sterile protective cover may be combined with an ophthalmic device, wherein the sterile protective cover is made of plastic, polythene, polyethylene, resin, rubber, polystyrene, polypropylene, polycarbonate, nylon, or combination thereof.

Abstract: The present invention relates to a rectal delivery device in the form of a syringe with improved locking mechanism for the delivery of an appropriate dosage of a medicament, thereby minimizing errors. More particularly, the present invention provides syringes with improved lock control units for delivering diazepam formulations for the treatment of patients experiencing epileptic seizures.

Abstract: Described herein is an intracameral therapeutic agent delivery device in the form of a pen-injector comprising a cartridge container for dispensing multiple doses of a medicament, coupled to an actuation assembly within a housing. A needle assembly is coupled to the distal end of the cartridge container, provided with a removable cap received within the housing will be in optional pre-sterile or no-sterile condition. Use of such device for the prevention or treatment of ocular conditions or diseases is also disclosed.

Abstract: The present invention discloses novel devices, methods, and formulations for multiple dose delivery of an appropriate formulation of Heparin or low molecular weight heparin or a heparin-like compound.

Abstract: Aspects of the present appliction relate to pharmaceutical formulations comprising bendamustine or its pharmaceutically acceptable salts, isomers, racemates, enantiomers, hydrates, solvates, metabolites, polymorphs, and mixtures therof, suitable for phamaceutical use. Aspects further provide methods of producing stable bendamustine compositions.

Abstract: The present application relates to compositions for parenteral administration of epothilone compounds, such as ixabepilone.

Abstract: Sustained release formulations comprising donepezil, or its pharmaceutically acceptable salts, and methods of preparing the sustained release formulations.

Abstract: The present application relates to compositions for parenteral administration of epothilone compounds, such as ixabepilone.

Abstract: Aspects of the present application relate to pharmaceutical formulations comprising a nonsteroidal anti-inflammatory drug, together with a proton pump inhibitor drug, to reduce the incidence of gastrointestinal complications associated with chronic therapy with a nonsteroidal anti-inflammatory drug. Specific aspects of the application relate to fixed dose combinations comprising aspirin, or a derivative thereof, and omeprazole or esomeprazole, or pharmaceutically acceptable salts, solvates, or hydrates thereof.